// App-Quantinova.ai

2275 : Impact of Apixaban On a Large Panel of Routine or More Specific Coagulation Assays.

Researchers

Presenter

  • Francois Mullier

Principal Investigators

  • Christian Chatelain

  • Bernard Chatelain

  • Dogne Jean-Michel

Medical Centers

  • Pharmacy,Namur Thrombosis and Hemostasis Center NTHC, Namur Research Institute for LIfe Sciences NARILIS, Facultes Universitaires Notre Dame de la Paix, Namur, Belgium

  • Hematology laboratory, UCL Mont-Godinne, Namur Research Institute for LIfe Sciences NARILIS, Yvoir, Belgium

  • Hematology laboratory, UCL Mont-Godinne, Namur Research Institute for LIfe Sciences NARILIS, Yvoir, Belgium

  • Pharmacy, Facultes Universitaires Notre Dame de la Paix, Namur, Belgium

Locations

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Non-valvular atrial fibrillation

  • Acute Coronary Syndromes

  • Venous thrombosis

  • Arrhythmia

  • Renal insufficiency

  • Stroke

  • Lupus

Biomarkers

  • Catalase

  • Coagulation Factor III, Tissue Factor

  • Prothrombin

Drug/Treatment

  • Fibrinogen (IV)

  • apixaban

  • Evithrom

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved